KETOROLAC TROMETHAMINE
KETOROLAC TROMETHAMINE is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: KETOROLAC TROMETHAMINE; Generic name: KETOROLAC TROMETHAMINE; Manufacturer: Leading Pharma, LLC.
| Brand name | KETOROLAC TROMETHAMINE |
|---|---|
| Generic name | KETOROLAC TROMETHAMINE |
| Manufacturer | Leading Pharma, LLC |
| Used for | INDICATIONS AND USAGE Carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. Acute Pain in Adult Patients Ketorolac tromethamine tablets are indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of ketorolac tromethamine and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessa |
| Dosage | DOSAGE AND ADMINISTRATION Carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. In adults, the combined duration of use of IV or IM dosing of ketorolac tromethamine and ketorolac tromethamine tablets is not to exceed 5 days. In adults, the use of ketorolac tromethamine tablets |
| Warnings | WARNINGS (see also Boxed WARNING) The total combined duration of use of ketorolac tromethamine tablets and IV or IM dosing of ketorolac tromethamine is not to exceed 5 days in adults. Ketorolac tromethamine tablets are not indicated for use in pediatric patients. The most serious risks associated with ketorolac tromethamine tablets are: Gastrointestinal Effects – Risk of Ulceration, Bleeding, and Perforation Ketorolac tromethamine is contraindicated in patients with previously documented peptic |
| Active ingredient(s) | KETOROLAC TROMETHAMINE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04df9620-6dcb-494a-83e2-6d28036be974 |